An Open-Label, Randomized, Four-Treatment, Four-Period, Single-Dose Crossover Study in Healthy Participants to Assess the Relative Bioavailability of AZD5004 in Three Solid Oral Formulations (F1, F3, F4)
Latest Information Update: 10 Jun 2025
At a glance
- Drugs AZD 5004 (Primary)
- Indications Liver disorders; Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 04 Jun 2025 New trial record
- 03 Jun 2025 Status changed from not yet recruiting to recruiting.